|Momenta Pharmaceuticals Inc -- USA Stock|| |
USD 18.40 0.65 3.66%
Co-Founder, Chief Scientific Officer and Sr. VP of Research
Dr. Ganesh Venkataraman Kaundinya, Ph.D., is Chief Operating Officer, Chief Scientific Officer of the Company. He is a cofounder of the Company and was the Company Chief Scientific Officer since September 2007. From September 2007 until his appointment as the Chief Operating Officer, Dr. Kaundinya was also a Senior Vice President of the Company. From April 2005 to September 2007, Dr. Kaundinya was the Company Senior Vice President, Research, and from January 2002 until April 2005, Dr. Kaundinya served as the Company Vice President, Technology
Age: 50 Founder Since 2017
Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Ganesh Kaundinya Latest Insider Activity
The company has return on total asset (ROA)
of (12.35) %
which means that it has lost $12.35 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (23.62) %
meaning that it created substantial loss on money invested by shareholders.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Momenta Pharmaceuticals operates under Drugs - Generic classification in USA and traded on NASDAQ. It employs 279 people.Momenta Pharmaceuticals Inc (MNTA) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 279 people. Momenta Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.